肥胖合并子宫内膜上皮内瘤变及子宫癌患者的减重治疗
基于Merative MarketScan数据库纳入15,374例18-70岁肥胖合并子宫内膜上皮内瘤变(EIN)或子宫癌患者,EIN患者诊断后1年内减重治疗使用率为8.6%,子宫癌患者为8.2%;EIN后减重治疗使用率从2009年4.1%升至2020年12.6%(P < .001),子宫癌后从4.9%升至11.4%(P < .001)。作者结论认为减重治疗使用率虽增加,但仍存在显著使用不足。
要点
- 肥胖合并EIN或子宫癌患者诊断后1年内减重治疗使用率分别为8.6%和8.2%。
- EIN后减重治疗使用率从2009年4.1%升至2020年12.6%(P < .001)。
- 子宫癌后减重治疗使用率从2009年4.9%升至2020年11.4%(P < .001)。
核心结论
- 减重治疗使用率有所增加,但在肥胖合并EIN或子宫癌患者中该辅助治疗仍存在显著使用不足。
研究设计与样本
- 使用Merative MarketScan数据库识别18-70岁肥胖且诊断为EIN或子宫癌的患者。
- EIN或子宫癌的主要治疗分为初次子宫切除术或激素治疗。
- 减重治疗包括营养咨询、减重手术和体重管理药物。
- 采用Cochran-Armitage检验分析减重治疗使用趋势,并建立多变量逻辑回归模型分析减重治疗使用的相关因素。
主要发现
- 共识别15,374例患者,其中EIN合并肥胖5,561例(36.2%),子宫癌合并肥胖9,813例(63.8%)。
- 诊断后1年内使用减重治疗者:EIN患者480例(8.6%),子宫癌患者802例(8.2%)。
- EIN诊断后任何减重治疗使用率从2009年4.1%升至2020年12.6%(P < .001)。
- 子宫癌诊断后任何减重治疗使用率从2009年4.9%升至2020年11.4%(P < .001)。
- 多变量回归模型中,较年轻年龄和高合并症评分与使用任何减重治疗的可能性较高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although obesity is an important risk factor for endometrial intraepithelial neoplasia (EIN) and uterine cancer, little is known about the trends in use of weight-loss therapy for patients with obesity with EIN and uterine cancer. We examined the use of weight-loss therapy among patients with obesity with EIN and uterine cancer. METHODS: The Merative MarketScan Database was used to identify patients aged 18-70 years who were obese and diagnosed with EIN or uterine cancer. The primary treatment for EIN or uterine cancer was categorized as either primary hysterectomy or hormonal therapy. Nutrition counseling, bariatric surgeries, and weight-management medications were identified as weight-loss therapy. We analyzed trends in the use of any weight-loss therapies with Cochran-Armitage tests. A multivariable logistic regression model was developed to examine factors associated with weight-loss therapy use. RESULTS: Overall, 15,374 patients were identified, including 5561 (36.2%) patients with EIN and obesity, and 9813 (63.8%) patients with uterine cancer and obesity. Weight-loss therapy was utilized within 1 year after diagnosis in 480 (8.6%) patients with EIN and in 802 (8.2%) patients with uterine cancer. Use of any weight-loss therapy after diagnosis of EIN increased from 4.1% in 2009 to 12.6% in 2020 (P < .001), and the use of any weight-loss therapy after diagnosis of uterine cancer increased from 4.9% in 2009 to 11.4% in 2020 (P < .001). In a multivariable regression model, younger age and patients with high comorbidity score were associated with a higher likelihood of using any weight-loss therapy. CONCLUSIONS: Use of weight-loss therapy has increased, however there is still a significant underuse of this adjunctive therapy in patients with obesity with EIN or uterine cancer.
引用
- Suzuki Y, Chen L, Matsuo K, et al. Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer. Gynecol Oncol. 2024. PMID: 39163750. doi:10.1016/j.ygyno.2024.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。